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a b s t r a c t
Here we present the application of our adeno-associated virus (AAV2) vector where transgene
expression is driven by a synthetic, p53-responsive promoter, termed PG, used to supply human
vascular endothelial growth factor-A165 (VEGF-A). Thus, p53 is harnessed to promote the beneﬁcial
expression of VEGF-A encoded by the AAVPG vector, bypassing the negative effect of p53 on HIF-1α
which occurs during cardiac hypertrophy. Wistar rats were submitted to pressure overload induced by
thoracic aorta coarctation (TAC) with or without concomitant gene therapy (intramuscular delivery in
the left ventricle). After 12 weeks, rats receiving AAVPG-VEGF gene therapy were compared to those that
did not, revealing signiﬁcantly improved cardiac function under hemodynamic stress, lack of ﬁbrosis and
reversal of capillary rarefaction. With these functional assays, we have demonstrated that application of
the AAVPG-VEGF vector under physiologic conditions known to stimulate p53 resulted in the
preservation of cardiac performance.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Pathologic cardiac hypertrophy is a chronic condition character-
ized by increased ventricular mass in response to an increased load
in the presence of hypertension, aortic stenosis, heart valve defects,
or myocardial infarction (Mill et al., 2011). Cardiac muscle hyper-
trophy can provide a short term beneﬁcial compensatory response
by reducing diastolic wall stress and increasing developed force,
but, at subsequent stages of cardiac remodeling, hypertrophy
culminates in contractile failure and ventricular dilatation (Frey
and Olson, 2003; Gardin and Lauer, 2004) and is associated with
increased morbidity and mortality (Levy et al., 1990).
The hypertrophic muscle mass develops disproportionally to
neovascularization, a mismatch that results in tissue hypoxia and
contributes to the transition to heart failure (Izumiya et al., 2006;
Shiojima et al., 2005). Hypoxia signals mediators that can satisfy the
demand for increased capillary density. For example, activation of
the transcription factor HIF-1α (hypoxia-inducible factor-1α) is
known to induce expression of vascular endothelial growth factor
(VEGF) and thus promote neovascularization (Carmeliet, 2000;
Forsythe et al., 1996; Tirziu and Simons, 2005). However, muscle
mass can accumulate faster than HIF-1α and VEGF can stimulate
angiogenesis, resulting in continued hypoxia, a cellular stress that
induces the accumulation of p53 (Das et al., 2010; Ravi et al., 2000;
Sano et al., 2007).
The p53 protein is a potent transcription factor (Beckerman and
Prives, 2010) and has been the subject of several studies related to
biomechanical stress and cardiac hypertrophy (Leri et al., 1998,
2000; Tsukamoto et al., 2006). Under hypoxic conditions, increased
p53 protein levels and activity were noted in heart cells (Das et al.,
2010; Long et al., 1997). The increase in p53 was associated with
inactivation of HIF-1α and reduction in VEGF expression (Ravi et al.,
2000; Sano et al., 2007). PUMA, a transcriptional target of p53 and
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activator of apoptosis, is also an important mediator of cell death in
the transition to heart failure (Mandl et al., 2011). Thus the p53
pathway plays a central role in down-regulating VEGF expression
and promoting cardiac cell death.
The mammalian VEGF family consists of the variants VEGF-A,
VEGF-B, VEGF-C, VEGF-D and placenta growth factor. All forms of
VEGF are secreted and may differ in binding afﬁnity with one, two
or all three VEGF receptors. Splice variants of VEGF-A yield a
variety of isoforms, though VEGF-A165 has been studied exten-
sively (Giacca and Zacchigna, 2012). Experimental studies have
shown that VEGF-A165 (referred to here as VEGF-A) is an essential
endothelial mitogenic agent in angiogenesis and vasculogenesis
(Pettersson et al., 2000), induces mitosis of adult cardiomyocytes
(Laguens et al., 2002) and is also associated with the recruitment
and activation of resident cardiac stem cells to repair sites of
ischemic tissue (Ferrarini et al., 2006; Vera Janavel et al., 2006).
Administration of recombinant VEGF-A has shown therapeutic
beneﬁt in animal models of cardiac hypertrophy induced by
transaortic coarctation (Friehs et al., 2006), though the adminis-
tration of recombinant protein may prove to be inefﬁcient for
prolonged treatments.
Gene therapy is a promising alternative to the application of
recombinant VEGF. The use of viral vectors that efﬁciently trans-
duce cardiac cells in vivo can provide localized concentrations of
VEGF, thus increasing the effect of the transgene (Giacca and
Zacchigna, 2012). In addition, gene therapy may provide an
opportunity for preemptive treatment, especially in the case that
the gene transfer vector provides on-demand expression of VEGF.
Controlled expression of VEGF is critical to avoid undesired effects
such as hemangioma formation (Lee et al., 2000; Schwarz et al.,
2000). To this end, our laboratory has developed several gene
transfer vectors where expression of the transgene is controlled by
p53 acting upon a synthetic p53-responsive promoter, termed PG.
We have shown that these retroviral, adenoviral and adeno-
associated virus vectors offer high-level expression only in the
presence of active p53 (Bajgelman et al., 2013; Bajgelman and
Strauss, 2008; Merkel et al., 2010; Strauss and Costanzi-Strauss,
2004). However, the use of adeno-associated virus (AAV) may be
especially well suited for cardiac gene transfer since these vectors
combine the advantages of low immune response against trans-
duced cells and the possibility of long term expressions of the
therapeutic gene (Bennett, 2003; Raake et al., 2008).
Here we propose a new therapeutic strategy to prevent the
deterioration of cardiac function associated with hypertrophy.
For this, we employed our adeno-associated vector which expresses
the human VEGF-A cDNA driven by a chimeric promoter responsive
to p53 (Bajgelman et al., 2013). In theory, as p53 levels increase
during the transition to decompensated cardiac hypertrophy, the
p53-responsive AAV vector should provide expression of VEGF-A.
In this way, the negative role of p53 in response to physiologic
stress is counterbalanced by using p53 to drive on-demand VEGF-A
transgene expression which, in turn, should contribute to neovas-
cularization and preservation of cardiac function.
Results
AAVPG-VIG provides p53-responsive expression of VEGF in transduced
primary cells
The AAVPG-VIG vector encodes the human VEGF-A165 (VEGF-A)
cDNA driven by the chimeric p53 responsive promoter, PGTxβ
(Bajgelman et al., 2013; Bajgelman and Strauss, 2008). In order to
verify the functionality of the vector in primary cardiac cells,
cardiomyocytes isolated from neonatal rat heart were transduced
with the AAVPG-VIG vector and subjected to increasing concen-
trations of doxorubicin, an anthracycline known to induce trans-
activation by p53, yielding signiﬁcant amounts of secreted human
VEGF-A, as measured in the cell culture medium by ELISA (Fig. 1A).
In Fig. 1B, we demonstrate that a similar response also occurs
using AAVPG-luc virus, encoding the luciferase reporter gene. The
fall in transgene expression at the highest drug dose may have
been due to toxicity, but this appears not to have altered vector
expression since the result is consistent even in the absence of
normalization (Fig. S1). These assays show that a treatment known
to activate p53 results in the induction of expression from AAVPG
vectors in a comparable manner.
We have directly tested whether the co-transduction of the AAVPG
and AAVCMV vectors is associated with any cross talk between the
vectors. As seen in Fig. S2, the performance of AAVPG-luc was
the same whether or not AAVCMV-LacZ was present. Therefore, the
co-transduction approach yields a reliable internal control.
In vivo cardiac transduction using viral vectors expressing the
LacZ reporter gene
We performed in vivo cardiac transduction followed by observa-
tion of β-galactosidase (LacZ) expression driven by the constitutive
CMV promoter. Wistar rats were injected in the left ventricle using
either 108 genome copies (GC) AAVCMV-LacZ (serotype 2) or 108
Fig. 1. Expression of AAVPG viruses can be induced in cardiomyocytes isolated from neonatal rat heart. (A) Cells were co-transduced with an equimolar mixture of the
adeno-associated vectors AAVPG-VIG and AAVCMV-LacZ. After 24 h, medium was changed and cells were subjected to the indicated concentrations of doxorubicin. Human
VEGF-A expression was quantiﬁed in the supernatant by ELISA, and normalized by β-gal activity presented by the cellular lysates. The condition without doxorubicin was
called 1. (B) Cells were co-transduced with an equimolar mix of the adeno-associated vectors AAVPG-luc and AAVCMV-LacZ. After 24 h, medium was changed and cells were
subjected to the indicated concentrations of doxorubicin. The cells were harvested and luciferase (Luc) activity was quantiﬁed. β-gal was used to normalize Luc activity. The
condition without doxorubicin was called 1. nPo0.05 and nnPo0.01 vs. control. One-way ANOVA followed by Bonferroni posthoc test. MeanþSEM, n¼3.
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Infectious Units (IU) of Adenovirus-CMV-LacZ (serotype 5). The
animals were euthanized after 4 weeks, hearts were removed,
processed and stained with X-Gal to verify the transduction
efﬁciency. Though both vectors resulted in cell marking, the AAV2
vector was qualitatively superior to Ad5 (Fig. S3). This result is
critical in conﬁrming that transduction of rat heart with AAV
serotype 2 was reliable. The use of other serotypes, such as 6 or
9, is known to yield higher rates of transduction (Asokan et al.,
2012), yet, as we will show, serotype 2 was adequate for our proof-
of-concept studies.
Transaortic constriction (TAC) is associated with activation of a p53
target gene and increased arterial systolic pressure
In order to evaluate the effect of stenosis on the activity of p53,
surgery including TAC or not (Sham) was performed. Data from
echocardiography showed no alteration with cardiac function
comparing TAC and Sham groups. As expected, animals submitted
to TAC displayed higher blood pressure (Fig. 2A). In this pilot assay,
animals were euthanized one week after TAC, total RNA collected
and expression of p21, a transcriptional target of p53, was
examined by qPCR. As seen in Fig. 2B, p21 levels were increased
in the TAC group. In this way, the expected rise in blood pressure
after TAC was also correlated with alteration in expression of a p53
target gene.
In vivo evaluation of the AAVPG-VIG vector: echocardiography
suggests a tendency to cardiac dysfunction in the TACþLUC group
We conducted an in vivo test where animals underwent surgery
including TAC or Sham operation and transduction with the
therapeutic vector, AAVPG-VIG (VIG), or a control vector, AAVPG-
Luc (LUC). The four experimental groups are referred to as
(i) ShamþLUC, (ii) ShamþVIG, (iii) TACþLUC, and (iv) TACþVIG.
Animals were examined by echocardiography at 4, 6, 8 and 12
weeks after the TAC (or Sham) procedure, yet alterations were
noted only at the ﬁnal time point, in agreement with the literature
(Litwin et al., 1995). At the end of this period, careful direct
hemodynamic study was performed.
Even after 12 weeks of follow-up, we observed only a slight
decrease in cardiac function, as measured by parameters such as
ejection fraction (EF) and fractional shortening (FS), in LUCþTAC
animals. Such a modest response to TAC is not without precedent
(Smeets et al., 2008). However, the VIGþTAC group showed a
tendency to maintain proper function (Fig. 3A and B). Since the
alterations were not statistically signiﬁcant, we used a more
sensitive assay that does not rely simply on base line functional
levels. To this end, the assessment of cardiac work under condi-
tions of hemodynamic stress was used to reveal functional
changes more clearly (dos Santos et al., 2010a).
Therapeutic beneﬁt of AAVPG-VIG treatment revealed upon induction
of sudden hemodynamic stresses
In agreement with the literature (dos Santos et al., 2010a;
Fletcher et al., 1982; Kumar et al., 1970), functional parameters
assessed by direct catheterization did not show signiﬁcant differ-
ences between our four experimental groups (Table S1). Using the
protocol previously described by dos Santos et al. (2010a), the
animals from the four experimental groups were subjected to
sudden pressure or volume alterations in order to induce hemo-
dynamic stress.
The induction of afterload stress, as expected, led to an increase in
systolic arterial pressure (50–70%) over the basal values for all
experimental groups (see Supplemental Fig. S4). Preload stresses
did not produce signiﬁcant changes on basal values. As seen in Fig. 3C
and D, the combination of the different hemodynamic stresses
induced signiﬁcant reduction in parameters of cardiac function, such
as stroke volume and stroke work generation, in all groups. Inter-
estingly, while Sham groups exhibited slight reductions on stroke
volume associated with increased recruitment of stroke work under
hemodynamic stresses, TACþLUC animals have a dramatic decrease
in ejected volume (Fig. 3C) with a clear reduction on stroke work
generation (Fig. 3D). Conversely, it was observed that the stroke
volume of TACþVIG group in response to the stress protocols was
equivalent to the Sham group, with signiﬁcant recruitment of stroke
work. Hence the induction of hemodynamic stress revealed func-
tional differences due to the TAC and gene therapy procedures. In this
experiment, the gene therapy approach of providing the AAVPG-VIG
vector was shown to be effective in preserving cardiac function.
Fig. 2. Physiological and molecular effects of TAC. (A) Systolic arterial pressure (SAP) and (B) qPCR for cardiac p21 expression in rats were evaluated 1 week after surgery. Increased
SAP observed in the carotid artery indicates efﬁciency of the TAC procedure when compared to the SHAM group. nPo0.05 by Student t test. MeanþSEM, Sham: n¼3, TAC: n¼2.
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Biometry and histomorphometry reveal that AAVPG-VIG treatment
preserved cardiac function, though it did not prevent hypertrophy
We analyzed the water content in the lungs to assess pulmonary
congestion as an index of cardiac decompensation. Although only
TACþLUC animals exhibited a tendency for increased lung water
content when compared to SHAMþLUC, with normal levels in
TACþVIG, a statistically signiﬁcant difference between TACþLUC
and TACþVIG was not reached (Fig. S5).
The ratio of heart/body mass in the TAC groups was signiﬁ-
cantly increased when compared to Sham (Fig. 4A). Histological
analysis on the remodeled myocardium showed a signiﬁcant
increase in the estimated volume of myocyte nuclei in the hearts
subjected to TAC, a parameter which was not signiﬁcantly inﬂu-
enced by VIG injection (Fig. 4B). These morphologic indicators of
hypertrophy, ratio of heart/body mass and volume of myocyte
nuclei, were not altered by AAVPG-VIG treatment, yet functional
parameters were preserved, as shown above.
Consistent with the notion that myocardial ﬁbrosis is asso-
ciated with loss of function, we observed that the interstitial
collagen content was signiﬁcantly increased only in the animals
treated with TACþLUC (Fig. 4C), the same group that showed
Fig. 3. Therapeutic virus enhanced cardiac function. (A) Echocardiography revealed a tendency for reduced ejection fraction in the TACþLUC group. The TACþVIG group,
which received therapeutic virus, showed a tendency to preserve cardiac function; however, this observation was not statistically signiﬁcant. Gray line represents normal
range for non-operated rats. (B) Echocardiography revealed a tendency to reduce fractional shortening in the TACþLUC group; however this observation was not statistically
signiﬁcant. The TACþVIG group, which received the therapeutic virus, was associated with preserved cardiac function. Gray line represents normal range for non-operated
rats. Effects of hemodynamic stress protocols on ejected stroke volume (C) and work generation (D) of all experimental groups. AS, afterload stress; MPS, mild preload stress;
SPS, severe preload stress. nPo0.05 vs. all groups; #Po0.05 vs. TACþLUC. Two-way ANOVA followed by Bonferroni posthoc. MeanþSEM, SHAMþLUC: n¼3, SHAMþVIG:
n¼5, TACþLUC: n¼4, and TACþVIG: n¼4.
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severe loss of function upon hemodynamic stress (Fig. 3C and D).
In contrast, the collagen content in the hearts from the TACþVIG
group was not different from the Sham groups, indicating that the
lack of ﬁbrosis was correlated with the preservation of cardiac
function by AAVPG-VIG treatment (Fig. 4C).
Finally, we evaluated the capillary density in the myocardium
from all experimental groups. As shown in Figs. 4D and S6, while
TACþLUC exhibited low capillary density when compared to Sham
groups, the therapy with AAVPG-VIG was able to counteract this
pathological change, preventing the capillary rarefaction that often
accompanies myocardial stress and hypertrophy. Since AAVPG-VIG
was shown to offer p53-responsive expression of VEGF-A in our
in vitro assays, we postulate that a similar mechanism was
responsible for regulating virus expression, and consequently
preserving capillary density, in vivo.
Discussion
The results of the present study provide practical evidence of the
functionality of a new therapeutic strategy to prevent deterioration
of cardiac function associated with hypertrophy. Since pathological
hypertrophy is associated with reduced capillary density, the cardiac
tissue can become hypoxic. The natural response is to induce HIF-1α
which, in turn, promotes the expression of VEGF. Over time, this
mechanism may prove insufﬁcient and tissues may suffer enough
stress that p53 becomes activated. Among its many functions, p53
can inhibit HIF-1α and bring about the loss of VEGF expression, thus
promoting the further deterioration of cardiac tissue and function.
To bypass this mechanism, we developed a vector derived from
adeno-associated virus, which contains the human VEGF-A165 cDNA
driven by a chimeric promoter responsive to p53, called PG. In this
scenario, the activation of p53 would induce VEGF expression and,
therefore, promote angiogenesis. The assays performed here indicate
that treatment with the AAVPG-VEGF vector can preserve cardiac
function even though it does not prevent the development of
hypertrophy itself.
The function of p53, the notorious tumor suppressor gene, did
not gain its fame based on its association with cardiopathies.
However, the fundamental role of p53 is to coordinate growth
arrest or death of cells that have suffered physiologic stress, such
as hypoxia. Many of the lessons of p53 activity learned in cancer
models may have application in the treatment of conditions such
as cardiac hypertrophy. The role of p53 in cardiovascular disease
may be underexplored, but its importance has been brought
to light.
Our prior work has focused on the development of viral gene
therapy vectors where transgene expression is controlled by p53.
As part of this work, we have previously described the construc-
tion of a chimeric p53-responsive promoter (PGTxβ, or simply PG)
and reporter assays that demonstrate robust expression in a
controlled manner, dependent on the activity of p53 (Bajgelman
and Strauss, 2008) and have explored the use of such vectors in
cancer models (Merkel et al., 2010; Strauss et al., 2005; Strauss and
Costanzi-Strauss, 2004). In a separate study using the AAVPG
vector, we have clearly shown its p53-responsiveness, including
when cells treated with doxorubicin, hypoxia or mechanical stress
(Bajgelman et al., 2013). We hypothesized that the application of
the AAVPG vector would be appropriate for cardiac hypertrophy
since, according to the literature, the accumulation of p53 occurs
in a transition phase, before the deterioration of cardiac function
from a compensated to a non-compensated state (Das et al., 2010;
Fig. 4. Histomorphometry shows that the therapeutic virus AAVPG-VIG prevented ﬁbrosis and capillary rarefaction in TAC animals. (A) TAC showed increased cardiac
hypertrophy index. (B) Histologic analysis of TAC animals revealed increased nuclear volume consistent with cardiac hypertrophy. (C) Myocardium stained with picrossirius
red for interstitial ﬁbrosis. (D) Myocardium stained with PAS to estimate capillary density. nPo0.05 vs. SHAM and #Po0.05 vs. TACþLUC. One-way ANOVA followed by
Bonferroni post-hoc test. MeanþSEM, SHAMþLUC: n¼3, SHAMþVIG: n¼5, TACþLUC: n¼4, and TACþVIG: n¼4.
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Sano et al., 2007). Hence, the p53-responsive mechanism should
provide virus expression during a critical phase of hypertrophy.
The properties of VEGF extend beyond the induction of angio-
genesis. It has been shown that intracardiac injection of VEGF
improves heart performance and inhibits cardiomyocyte apoptosis
(Ruixing et al., 2007), induces the mitosis of adult cardiomyocytes
(Laguens et al., 2002), induces hyperplasia of cardiomyocytes
(Laguens et al., 2004) and it has been suggested that it also
participates in the mobilization of stem cells for cardiac tissue
repair (Ferrarini et al., 2006). Our observations are consistent with
these reports since our experimental results in animals that
underwent TAC and received the therapeutic AAVPG-VIG virus
were associated with preservation of cardiac function that was
correlated with preservation of capillary density and the lack of
ﬁbrosis, yet animals that did not receive gene therapy suffered loss
of function, capillary rarefaction and induction of ﬁbrosis.
The morphologic signs of hypertrophy upon TAC, such as
increased heart/body weight ratio and nuclear volume, persisted
even though cardiac function was preserved with AAVPG-VIG
treatment. The heart/body weight ratio did reveal a statistically
signiﬁcant increase with TAC, though we point out that body
weight was not altered and that peripheral edema was not
observed, contributing to the reliability of the observed ratio.
Moreover, our morphologic observations were well substantiated
by the histologic evaluation and both methods point to the
appearance of hypertrophy in the TAC groups.
Further studies are required, but the preservation of function
appears to be related to the maintenance of capillary density and
reduction of collagen deposition. At this time we can only speculate
as to whether the capillaries were indeed preserved or if they
represent neovascularization. The latter scenario does seem likely
since heart mass was increased without loss of capillary density,
suggesting that new vessels were formed during the remodeling
process. Our attempts to quantify neovascularization were met with
technical difﬁculties, but we did count vessels upon staining with
PAS. Even so, the functional result supports the notion that treat-
ment with AAVPG-VIG preserved cardiac performance.
The TAC procedure did not yield profound alterations in
ejection fraction or fractional shortening when measured at base
line (in the absence of additional hemodynamic stress). This result
is not without precedent as it has been observed in several animal
models (Smeets et al., 2008). Moreover, the concept of cardiac
reserve, the heart's ability to perform beyond its basal level,
supports the notion that the impact of TAC may not be seen
without added stress (dos Santos et al., 2010a). We do not rule out
the possibility that a longer follow-up period may have revealed
base line alterations due to our TAC procedure. Alternatively, a
more acute model, such as induction of infarct, may be used in
future studies in order to reveal pronounced changes in heart
function. In the present study, the beneﬁt of the AAVPG-VIG vector
was revealed when sudden hemodynamic stress was applied. This
method is sufﬁciently sensitive such that changes in cardiac
function are revealed even in animals that had no visible changes
under basal conditions (dos Santos et al., 2010a). Such an approach
supports analysis of heart function at stages that precede obvious
deterioration and it has been used to assess strategies to prevent
cardiac deterioration post-myocardial infarction using transplan-
tation of ﬁbroblast cells genetically modiﬁed to express VEGF or
adult stem cells of different origins (Danoviz et al., 2010; dos
Santos et al., 2010b; Goncalves et al., 2010; Nakamuta et al., 2009).
The outﬂow constriction by aortic coarctation is clearly a model of
cardiac hypertrophy rather than of heart failure. In addition, it is
already consensual that this model does not mimic the most
common clinical condition of cardiac hypertrophy related to essential
hypertension, mainly because we cannot be sure that the dynamics
of the hypertrophy process after an acute pressure overload is
equivalent to that observed gradually in hypertensive humans.
Notwithstanding, this model has been intensively used during the
last two decades as a rat model for pathophysiological and ther-
apeutic investigations, since the partial aortic constriction has low
mortality during surgery and rapidly leads to cardiac remodeling
including hypertrophy, ﬁbrosis, apoptosis and capillary rarefaction,
accompanied by late evidences of heart failure such as afterload
mismatch, reduced ejection fraction and lung congestion seen here
12 weeks after TAC.
The in vivo transduction efﬁciency seemed to be sufﬁcient to
bring about the desired functional result. Since we used a
relatively low titer AAV2 as compared to examples from the
literature (Aikawa et al., 2002; Kimura et al., 2001; Raake et al.,
2008; Su et al., 2004), the transduction level may have been
suboptimal, though this was not tested directly. Even though the
use of serotypes 6 and 9 would be more appropriate in a cardiac
model (Asokan et al., 2012), the functional beneﬁt of our AAV2
vector was clearly evident. The use of AAV6 or 9 may facilitate
intravenous administration of the vector, yet the functional results
of this proof-of-concept study indicate that we encountered no
shortcoming with the intramuscular delivery of AAV2.
AAV vectors have several features that make them especially
appropriate for gene therapy in the cardiovascular system in
general and applicable to hypertrophy in particular. These vectors
are quite stable and provide long-term expression of the transgene,
yet do not, for the most part, integrate in the genome of the host
cells. AAV vectors are also much less likely to provoke an immune
response than an adenoviral vector (Bennett, 2003; Li et al., 2007).
These features, as well as the p53-responsive transcriptional con-
trol, contribute to the vigilant aspect of the AAVPG-VIG vector. As
was performed here, the AAVPG-VIG vector can be administered
before hypertrophy has taken hold with the expectation that
expression of the therapeutic gene be induced as needed. Such
‘on demand’ expression of VEGF should lessen the likelihood of
hemangioma formation (Lee et al., 2000; Schwarz et al., 2000).
The strategy presented here will require additional reﬁnements
before consideration for clinical application. For example, the
AAVPG-VIG vector expresses the transgene when p53 is activated,
but is not speciﬁc for cardiac cells. In order to improve safety,
additional mechanisms may be incorporated to ensure that the
vector expresses only in heart cells in addition to the conditional
expression regulated by p53. As mentioned above, the AAV vector
can also be improved by changing the viral capsid in order to
direct tissue tropism according to the viral serotype (Asokan et al.,
2012; Palomeque et al., 2007), thus enhancing transductional
speciﬁcity of cardiac cells.
We hypothesize that this gene therapy approach may be
especially well suited to the preservation of cardiac function while
other treatments are sought to relieve the underlying cause of
pressure overload such as in chronic hypertensive patients. In
other words, this pre-emptive strategy may be suited to preserve
cardiac function even if hypertrophy is not fully reversed or
prevented. In fact, we believe that this strategy could be very
useful since it can potentially modulate the pathological process in
an ‘on demand’ manner depending on the injury degree and the
phase of the disease, especially considering that the vector used
here could induce expression of the transgene (such as therapeutic
VEGF) with a damage-responsive promoter (such as PG, used in
this study).
We conclude that the new AAV viral vector encoding the VEGF-A
cDNA driven by the chimeric promoter responsive to p53 combines
the advantages of low immunogenicity, high transduction efﬁciency,
robust and controlled expression which is induced on demand by
hypertrophic cells and may be used for the development of new
therapeutic approaches to preserve cardiac function associated with
cardiac hypertrophy.
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Material and methods
Cell culture and lines
The adenovirus-transformed, human embryo kidney cell line 293T
was maintained in DMEM (Life Technologies, USA) supplemented
with 10% FBS (HyClone, USA), 100 mg/mL gentamycin, 50 mg/mL
ampicillin, and 2.5 mg/mL fungizone, at 37 1C, in a humidiﬁed atmo-
sphere of 5% CO2. Cardiomyocytes were isolated from neonate Wistar
rats as previously described (Barreto-Chaves et al., 2000).
Vector construction
The AAV Helper-Free System (Stratagene-USA), which provides
AAV2 genome and packaging vectors, was modiﬁed to become
compatible with the Gateway site speciﬁc recombination system
and pEntr vectors (Invitrogen Life Technologies) and has been
described elsewhere (Bajgelman et al., 2013). Brieﬂy, we con-
structed pAAV-dest by cloning the recombination site excised from
pcDNA/V5-DEST (Invitrogen) into pAAVCMV (Stratagene) after
removing the CMV promoter/enhancer sequences. To generate
the pEntr vector, we used PCR to amplify the expression cassette
PGTxβ-eGFP from pAdPG-eGFP (Bajgelman and Strauss, 2008) and
inserted this into pEntr-2D-topo (Invitrogen). The plasmid was
digested to excise GFP and to insert a new cassette encoding VEGF-
Ires-GFP (VIG) which was excised from pCMV-VEGF-Ires-GFP
(Becker et al., 2006; Goncalves et al., 2010), generating pEntr-PG-
VEGF-Ires-eGFP where both human VEGFA165 and enhanced green
ﬂuorescent protein are expressed in a single transcript. Recombi-
nation with pAAV-dest yielded the AAVPG-VIG vector. A similar
strategy was used to produce AAVPG-Luc (luciferase) (Bajgelman
et al., 2013). AAVCMV-LacZ was purchased from Stratagene. Clon-
ing details can be provided upon request.
Preparation of AAV
Viral preparations were transiently produced by co-transfection
of 293T cells with the viral plasmid and packaging plasmids
(conferring an AAV2 capsid) from the AAV Helper-Free System
(Stratagene-USA). The supernatants and cell lysates were harvested
and virus was puriﬁed using the AAV Puriﬁcation Kit (Cell Biolabs-
USA). Titration was done by qPCR, where a standard curve was
generated using the plasmid form of the AAV vector and vector titer
is measured as genome copies (GC)/ml. Preps were treated with
DNAse before qPCR was performed in order to assure measurement
of only encapsidated genomes. The primers used for titration
of AAVPG-Luc and AAVPG-VIG amplify within the polyadeny-
lation sequence: F-PA 50-ATCTCCCCCTGAACCTGAA-30 and R-PA
50-CGCTTCGAGCAGACATGA-30. Whereas AAV-LacZ, which employs
a different polyadenylation sequence, was titered with primers
speciﬁc for this region: lacz-F-PA 50-GGCCCAACTTGTTTATTGC-30
and lacz-R-PA 50-CCGGAGATCCAGACATGAT-30.
In vitro assays: VEGF-A, luciferase and β-Gal quantitation
Primary cells were transduced with AAVPG-VIG using 100 GC/
target cell. After 24 h media was changed and the indicated
amounts of doxorubicin were added to induce p53 and the cells
were incubated at 37 1C for an additional 24 h. Then the super-
natant was harvested to quantify the human VEGF-A secreted by
the transduced cells, using an ELISA kit manufactured by R&D
System Inc – USA.
Alternatively, cells were harvested and lysed in 0.1% Triton
X-100, 0.1 M Tris/HCl, pH 8.0 by a freeze/thaw treatment. The lysate
was then clariﬁed by centrifugation, 5 min, 10,000 rpm. The super-
natant was transferred to a fresh tube and stored at 20 1C. For
luciferase assay, 10 ml of lysate was added to 50 ml of LAR (Promega,
USA), and activity was measured using a luminometer. Luc activity
was normalized by total protein, measured using Bradford reagent
(Bio-Rad, USA). For the β-galactosidase assay, 30 ml of lysate was
added to 100 ml of ONPG solution (77 ml of 0.1 M Na2HPO4, pH7.5,
22 ml of 4 mg/ml ONPG, 1 ml of 0.1 M MgCl2, and 4.5 M 2-mercap-
toethanol) in a 96 well plate. The reactions were allowed to proceed
for 5–15 min, 37 1C, and stopped using a 1 M sodium carbonate
solution. Absorbance measurements were made at 405 nm using a
microtiter plate reader. Beta gal activity was normalized by total
protein, measured using Bradford reagent (Bio-Rad, USA).
In vivo transduction and β-Gal assay
Male Wistar rats (3 months of age) were fed with standard
laboratory chow and givenwater ad libitum, housed in a temperature-
controlled room (22 1C) with a dark–light cycle of 12–12 h. All
experimental procedures followed institutional guidelines for care
and use of laboratory animals, and the protocols were approved by
the Institutional Review Board of the University of São Paulo Medical
School, Brazil.
In brief, rats were anesthetized by a mixture of ketamine
(90 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). After endotracheal
intubation, mechanical ventilation was initiated (model 683,
Harvard Apparatus) with a volume of 10 ml/kg and a respiratory
rate of 90/min. Animals were injected at ﬁve points in the left
ventricle with 108 GC of either AdCMV-LacZ or AAVCMV-LacZ
virus, as indicated, in a ﬁnal volume of 100 ml. The chest was closed
with 4-0 nylon sutures, the pneumothorax was evacuated, and rats
were extubated and allowed to recover from the anesthesia.
After four weeks, rats were anesthetized by a mixture of
ketamine (90 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.), and the
hearts were removed. Each heart was washed in saline, cut into
three parts, from base to apex, mechanically ﬁxed to a sheet of
cork with Tissue Tec and frozen in isopentane bath and liquid
nitrogen. Next, we made 7 μm cuts. The sections were stained
with X-Gal solution and incubated overnight in a humidiﬁed
chamber at 37 1C.
In vivo therapeutic role of AAVPG-VIG
Male Wistar rats (3 months of age) were fed with standard
laboratory chow and given water ad libitum, housed in a
temperature-controlled room (22 1C) with a dark–light cycle of
12–12 h. All experimental procedures followed institutional guide-
lines for care and use of laboratory animals, and the protocols
were approved by the Institutional Review Board of the University
of São Paulo Medical School, Brazil.
We used the cardiac hypertrophy model induced by thoracic
aorta surgical constriction (TAC). In brief, rats were anesthetized
by a mixture of ketamine (90 mg/kg, i.p.) and xylazine (10 mg/kg, i.
p.). After endotracheal intubation, mechanical ventilation was
initiated (model 683, Harvard Apparatus) with a volume of
10 ml/kg and a respiratory rate of 90/min. The chest cavity was
entered in the third intercostal space, and the thoracic aorta was
isolated. We performed thoracic aorta constriction by tying the
vessel with a 2-0 nylon suture ligature against an 18-gauge needle.
A sham surgery was performed as a control, without aortic
narrowing. Immediately after performing TAC or sham surgery,
animals were injected at ﬁve points in the left ventricle with
control (AAVPG-LUC) or therapeutic viruses (AAVPG-VIG). In each
case, the total volume injected was 100 ml of a preparation
containing 109 GC/ml. The chest was closed with 4-0 nylon
sutures, the pneumothorax was evacuated, and rats were extu-
bated and allowed to recover from the anesthesia.
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Assessment of cardiac function by echocardiography and
hemodynamics
After 12 weeks of follow-up, morpho-functional evaluation by
Doppler echocardiography was performed on the anesthetized
animals 5 min after intraperitoneal injection of a mixture of
ketamine (90 mg/kg) and xylazine (10 mg/kg). The images were
obtained with a high-resolution 15 MHz transducer able to acquire
real time images in small animals (SEQUOIA 512, ACUSON Cor-
poration, Mountain View, CA), performed by a practiced echocar-
diographer (R.A. Sirvente) without knowledge of the animal
condition or experimental group. Echocardiagraphy was per-
formed during a 2 min period. M-mode and bi-dimensional mode
(B-mode) were used to obtain the intracavitary dimensions and
septal wall thicknesses in diastole and systole. Systolic function
was estimated calculating the fractional shortening (FS) according
to the ratio of LV dimensions [(dLVsLV)100/dLV], with LV
internal dimensions obtained by M-mode during systole and
diastole in the same cardiac cycle; and by ejection fraction (EF)
using the ratio of LV volumes obtained by the Simpson biplane
method. For evaluation of the LV diastolic function, the isovolumic
relaxation time (IVRT) was assessed by moving the pulsed Doppler
volume sample slightly toward the LV outﬂow tract to obtain
simultaneous transmitral diastolic ﬂow and systolic aortic ﬂow.
This parameter includes the time between aortic valve closure and
mitral valve opening, representing the period of isovolumic LV
relaxation (Nagueh et al., 2009).
24 h after echocardiogram examinations, hemodynamic study
with direct ventricular catheterization was done as previously
described. In brief, after anesthesia with the same mixture of
ketamine plus xylazine, a micro-manometer (MikroTip™ 2F;
Millar Instruments Inc., Houston, TX, USA) was inserted into the
LV cavity through the carotid artery to measure the intraventri-
cular pressure. Through a small right thoracotomy, a ﬂow ultra-
sound probe (Transonic Systems Inc., Ithaca, NY, USA) was
positioned around the ascending aorta to estimate LV ejection.
Protocols were performed in closed chests and the following
parameters were analyzed: LV systolic and end-diastolic pressures,
rate of change of LV pressure, heart rate, cardiac output, stroke
volume and stroke work. Stroke work was calculated as the
product of stroke volume (systolic pressureend-diastolic LV
pressure). After evaluation under basal conditions, cardiac perfor-
mance was tested by acquiring these parameters under different
levels of hemodynamic stress. Sudden afterload increase (AS,
afterload stress) was performed by a single vasoconstrictive
phenylephrine intravenous injection (PHE, l-phenylephrine hydro-
chloride, Sigma, St. Louis, MO, USA), with doses individually
adjusted (15–25 μg/kg) to produce comparable blood pressure
increases of 50–70% over the baseline. After return to baseline,
moderate preload stress (MPS) was induced by volume overload
where 3 ml/kg of 6% dextran was injected intravenously and
followed by the same afterload stress described above. After
pressure had returned once again to baseline, severe preload
stress (SPS) was induced (6% dextran 2 ml/kg) and followed
immediately by sudden afterload stress.
Biometry, cardiac histology and morphometry
After hemodynamic study, the right lung was excised and both
the wet and dry masses (drying at 80 1C for 12 h) were determined
to estimate the water content (mass loss after drying as a
percentage of the wet mass). The heart was excised and weighed
in order to use the ventricle mass divided by the body mass as an
index suggestive of ventricular hypertrophy. Thereafter, the heart
was ﬁxed in 10% buffered formalin for 24 h, embedded in parafﬁn,
and transversely cut into 3 mm sections. Sections were mounted
onto slides and stained with hematoxylin and eosin for myocyte
analysis, picrossirius red for ﬁbrosis evaluation, or periodic acid-
Schiff (PAS) for capillary density quantiﬁcation. A computerized
image acquisition system (Leica Imaging Systems, Bannockburn,
IL, USA) was used for the analyses. Histological analysis was
performed blinded to the experimental group. As an estimate of
myocyte hypertrophy, the average nuclear volume was deter-
mined randomly in 5070 myocytes cut longitudinally for each
animal, and calculated according to the following equation:
nuclear volume¼πD d2/6 where d¼shorter nuclear diameter
and D¼ longer nuclear diameter (Gerdes et al., 1994). Fibrosis in
the remote non-infarcted LV was considered as the collagen ﬁbers
not including perivascular ﬁbers. After digitalization, the red-
stained areas were quantiﬁed as the average percentage of the
total area from each of 5 randomized 200 magniﬁcation ﬁelds
per animal. Capillary density was evaluated in 6 randomized
400 magniﬁcation ﬁelds per animal, where the ﬁbers were cut
transversally, being expressed as the total capillary amount per
area (capillaries/mm2).
Acknowledgments
We thank Newton Lopes, Monica Nunes and Samantha Omae for
animal care, technical assistance for surgeries and cardiomyocyte
isolation. We also thank Ayumi Aurea Miyakawa, Julliana Carvalho
de Campos and Camila Zogbi Noqueira for their expert assistance
with histologic assays. This work was supported by CNPq (MCB,
478381/2007-7) and the São Paulo Research Foundation, FAPESP
(MCB, 2007/54480-2; BES, 2007/50210-0 and 2011/50911-4).
Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2014.12.009.
References
Aikawa, R., Huggins, G.S., Snyder, R.O., 2002. Cardiomyocyte-speciﬁc gene expres-
sion following recombinant adeno-associated viral vector transduction. J. Biol.
Chem. 277 (21), 18979–18985.
Asokan, A., Schaffer, D.V., Samulski, R.J., 2012. The AAV vector toolkit: poised at the
clinical crossroads. Mol. Ther. 20 (4), 699–708.
Bajgelman, M.C., Medrano, R.F., Carvalho, A.C., Strauss, B.E., 2013. AAVPG: a vigilant
vector where transgene expression is induced by p53. Virology 447 (1–2),
166–171.
Bajgelman, M.C., Strauss, B.E., 2008. Development of an adenoviral vector with
robust expression driven by p53. Virology 371 (1), 8–13.
Barreto-Chaves, M.L., Heimann, A., Krieger, J.E., 2000. Stimulatory effect of dex-
amethasone on angiotensin-converting enzyme in neonatal rat cardiac myo-
cytes. Braz. J. Med. Biol. Res. 33 (6), 661–664.
Becker, C., Lacchini, S., Muotri, A.R., da Silva, G.J., Castelli, J.B., Vassallo, P.F., Menck,
C.F., Krieger, J.E., 2006. Skeletal muscle cells expressing VEGF induce capillary
formation and reduce cardiac injury in rats. Int. J. Cardiol. 113 (3), 348–354.
Beckerman, R., Prives, C., 2010. Transcriptional regulation by p53. Cold Spring Harb.
Perspect. Biol. 2 (8), a000935.
Bennett, J., 2003. Immune response following intraocular delivery of recombinant
viral vectors. Gene Ther. 10 (11), 977–982.
Carmeliet, P., 2000. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6 (4),
389–395.
Danoviz, M.E., Nakamuta, J.S., Marques, F.L., dos Santos, L., Alvarenga, E.C., dos
Santos, A.A., Antonio, E.L., Schettert, I.T., Tucci, P.J., Krieger, J.E., 2010. Rat
adipose tissue-derived stem cells transplantation attenuates cardiac dysfunc-
tion post infarction and biopolymers enhance cell retention. PLoS One 5 (8),
e12077.
Das, B., Young, D., Vasanji, A., Gupta, S., Sarkar, S., Sen, S., 2010. Inﬂuence of p53 in
the transition of myotrophin-induced cardiac hypertrophy to heart failure.
Cardiovasc. Res. 87 (3), 524–534.
dos Santos, L., Antonio, E.L., Souza, A.F., Tucci, P.J., 2010a. Use of afterload
hemodynamic stress as a practical method for assessing cardiac performance
in rats with heart failure. Can. J. Physiol. Pharmacol. 88 (7), 724–732.
M.C. Bajgelman et al. / Virology 476 (2015) 106–114 113
dos Santos, L., Santos, A.A., Goncalves, G.A., Krieger, J.E., Tucci, P.J., 2010b. Bone
marrow cell therapy prevents infarct expansion and improves border zone
remodeling after coronary occlusion in rats. Int. J. Cardiol. 145 (1), 34–39.
Ferrarini, M., Arsic, N., Recchia, F.A., Zentilin, L., Zacchigna, S., Xu, X., Linke, A.,
Giacca, M., Hintze, T.H., 2006. Adeno-associated virus-mediated transduction of
VEGF165 improves cardiac tissue viability and functional recovery after
permanent coronary occlusion in conscious dogs. Circ. Res. 98 (7), 954–961.
Fletcher, P.J., Pfeffer, J.M., Pfeffer, M.A., Braunwald, E., 1982. Effects of hypertension
on cardiac performance in rats with myocardial infarction. Am. J. Cardiol. 50 (3),
488–496.
Forsythe, J.A., Jiang, B.H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R.D., Semenza, G.L.,
1996. Activation of vascular endothelial growth factor gene transcription by
hypoxia-inducible factor 1. Mol. Cell. Biol. 16 (9), 4604–4613.
Frey, N., Olson, E.N., 2003. Cardiac hypertrophy: the good, the bad, and the ugly.
Annu. Rev. Physiol. 65, 45–79.
Friehs, I., Barillas, R., Vasilyev, N.V., Roy, N., McGowan, F.X., del Nido, P.J., 2006.
Vascular endothelial growth factor prevents apoptosis and preserves contrac-
tile function in hypertrophied infant heart. Circulation 114 (1 Suppl),
S290–S295.
Gardin, J.M., Lauer, M.S., 2004. Left ventricular hypertrophy: the next treatable,
silent killer? J. Am. Med. Assoc. 292 (19), 2396–2398.
Gerdes, A., Liu, Z., Zimmer, H., 1994. Changes in nuclear size of cardiac myocytes
during the development and progression of hypertrophy in rats. Cardioscience
5 (3), 203–208.
Giacca, M., Zacchigna, S., 2012. VEGF gene therapy: therapeutic angiogenesis in the
clinic and beyond. Gene Ther. 19, 622–629.
Goncalves, G.A., Vassallo, P.F., dos Santos, L., Schettert, I.T., Nakamuta, J.S., Becker, C.,
Tucci, P.J., Krieger, J.E., 2010. Intramyocardial transplantation of ﬁbroblasts
expressing vascular endothelial growth factor attenuates cardiac dysfunction.
Gene Ther. 17 (3), 305–314.
Izumiya, Y., Shiojima, I., Sato, K., Sawyer, D.B., Colucci, W.S., Walsh, K., 2006.
Vascular endothelial growth factor blockade promotes the transition from
compensatory cardiac hypertrophy to failure in response to pressure overload.
Hypertension 47 (5), 887–893.
Kimura, B., Mohuczy, D., Tang, X., Phillips, M.I., 2001. Attenuation of hypertension
and heart hypertrophy by adeno-associated virus delivering angiotensinogen
antisense. Hypertension 37 (2 Part 2), 376–380.
Kumar, R., Hood Jr., W.B., Joison, J., Norman, J.C., Abelmann, W.H., 1970. Experi-
mental myocardial infarction. II. Acute depression and subsequent recovery of
left ventricular function: serial measurements in intact conscious dogs. J. Clin.
Investig. 49 (1), 55–62.
Laguens, R., Cabeza Meckert, P., Vera Janavel, G., De Lorenzi, A., Lascano, E., Negroni,
J., Del Valle, H., Cuniberti, L., Martinez, V., Dulbecco, E., Melo, C., Fernandez, N.,
Criscuolo, M., Crottogini, A., 2004. Cardiomyocyte hyperplasia after plasmid-
mediated vascular endothelial growth factor gene transfer in pigs with chronic
myocardial ischemia. J. Gene Med. 6 (2), 222–227.
Laguens, R., Cabeza Meckert, P., Vera Janavel, G., Del Valle, H., Lascano, E., Negroni,
J., Werba, P., Cuniberti, L., Martinez, V., Melo, C., Papouchado, M., Ojeda, R.,
Criscuolo, M., Crottogini, A., 2002. Entrance in mitosis of adult cardiomyocytes
in ischemic pig hearts after plasmid-mediated rhVEGF165 gene transfer. Gene
Ther. 9 (24), 1676–1681.
Lee, R.J., Springer, M.L., Blanco-Bose, W.E., Shaw, R., Ursell, P.C., Blau, H.M., 2000.
VEGF gene delivery to myocardium: deleterious effects of unregulated expres-
sion. Circulation 102 (8), 898–901.
Leri, A., Claudio, P.P., Li, Q., Wang, X., Reiss, K., Wang, S., Malhotra, A., Kajstura, J.,
Anversa, P., 1998. Stretch-mediated release of angiotensin II induces myocyte
apoptosis by activating p53 that enhances the local renin-angiotensin system
and decreases the Bcl-2-to-Bax protein ratio in the cell. J. Clin. Investig. 101 (7),
1326–1342.
Leri, A., Fiordaliso, F., Setoguchi, M., Limana, F., Bishopric, N.H., Kajstura, J., Webster, K.,
Anversa, P., 2000. Inhibition of p53 function prevents renin-angiotensin system
activation and stretch-mediated myocyte apoptosis. Am. J. Pathol. 157 (3),
843–857.
Levy, D., Garrison, R.J., Savage, D.D., Kannel, W.B., Castelli, W.P., 1990. Prognostic
implications of echocardiographically determined left ventricular mass in the
Framingham heart study. N. Engl. J. Med. 322 (22), 1561–1566.
Li, H., Murphy, S.L., Giles-Davis, W., Edmonson, S., Xiang, Z., Li, Y., Lasaro, M.O., High, K.A.,
Ertl, H.C., 2007. Pre-existing AAV capsid-speciﬁc CD8þ T cells are unable to
eliminate AAV-transduced hepatocytes. Mol. Ther. 15 (4), 792–800.
Litwin, S.E., Katz, S.E., Weinberg, E.O., Lorell, B.H., Aurigemma, G.P., Douglas, P.S.,
1995. Serial echocardiographic-Doppler assessment of left ventricular geome-
try and function in rats with pressure-overload hypertrophy. Chronic
angiotensin-converting enzyme inhibition attenuates the transition to heart
failure. Circulation 91 (10), 2642–2654.
Long, X., Boluyt, M.O., Hipolito, M.L., Lundberg, M.S., Zheng, J.S., O’Neill, L., Cirielli, C.,
Lakatta, E.G., Crow, M.T., 1997. p53 and the hypoxia-induced apoptosis of cultured
neonatal rat cardiac myocytes. J. Clin. Investig. 99 (11), 2635–2643.
Mandl, A., Pham, L.H., Toth, K., Zambetti, G., Erhardt, P., 2011. Puma deletion delays
cardiac dysfunction in murine heart failure models thgrough attenuation of
apoptosis. Circulation 124, 31.
Merkel, C.A., da Silva Soares, R.B., de Carvalho, A.C., Zanatta, D.B., Bajgelman, M.C.,
Fratini, P., Costanzi-Strauss, E., Strauss, B.E., 2010. Activation of endogenous p53
by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in
the murine cell lines B16 and C6. BMC Cancer 10, 316.
Mill, J.G., Stefanon, I., dos Santos, L., Baldo, M.P., 2011. Remodeling in the ischemic
heart: the stepwise progression for heart. Braz. J. Med. Biol. Res. 44 (9),
890–898.
Nagueh, S.F., Appleton, C.P., Gillebert, T.C., Marino, P.N., Oh, J.K., Smiseth, O.A.,
Waggoner, A.D., Flachskampf, F.A., Pellikka, P.A., Evangelista, A., 2009. Recommen-
dations for the evaluation of left ventricular diastolic function by echocardiogra-
phy. J. Am. Soc. Echocardiogr. 22 (2), 107–133.
Nakamuta, J.S., Danoviz, M.E., Marques, F.L., dos Santos, L., Becker, C., Goncalves, G.A.,
Vassallo, P.F., Schettert, I.T., Tucci, P.J., Krieger, J.E., 2009. Cell therapy attenuates
cardiac dysfunction post myocardial infarction: effect of timing, routes of injection
and a ﬁbrin scaffold. PLoS One 4 (6), e6005.
Palomeque, J., Chemaly, E.R., Colosi, P., Wellman, J.A., Zhou, S., Del Monte, F., Hajjar,
R.J., 2007. Efﬁciency of eight different AAV serotypes in transducing rat
myocardium in vivo. Gene Ther. 14 (13), 989–997.
Pettersson, A., Nagy, J.A., Brown, L.F., Sundberg, C., Morgan, E., Jungles, S., Carter, R.,
Krieger, J.E., Manseau, E.J., Harvey, V.S., Eckelhoefer, I.A., Feng, D., Dvorak, A.M.,
Mulligan, R.C., Dvorak, H.F., 2000. Heterogeneity of the angiogenic response
induced in different normal adult tissues by vascular permeability factor/
vascular endothelial growth factor. Lab. Investig. 80 (1), 99–115.
Raake, P.W., Hinkel, R., Muller, S., Delker, S., Kreuzpointner, R., Kupatt, C., Katus, H.A.,
Kleinschmidt, J.A., Boekstegers, P., Muller, O.J., 2008. Cardio-speciﬁc long-term
gene expression in a porcine model after selective pressure-regulated retro-
infusion of adeno-associated viral (AAV) vectors. Gene Ther. 15 (1), 12–17.
Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., Dillehay,
L.E., Madan, A., Semenza, G.L., Bedi, A., 2000. Regulation of tumor angiogenesis
by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev.
14 (1), 34–44.
Ruixing, Y., Dezhai, Y., Hai, W., Kai, H., Xianghong, W., Yuming, C., 2007. Intramyo-
cardial injection of vascular endothelial growth factor gene improves cardiac
performance and inhibits cardiomyocyte apoptosis. Eur. J. Heart Fail. 9 (4),
343–351.
Sano, M., Minamino, T., Toko, H., Miyauchi, H., Orimo, M., Qin, Y., Akazawa, H., Tateno, K.,
Kayama, Y., Harada, M., Shimizu, I., Asahara, T., Hamada, H., Tomita, S., Molkentin, J.D.,
Zou, Y., Komuro, I., 2007. p53-induced inhibition of Hif-1 causes cardiac dysfunction
during pressure overload. Nature 446 (7134), 444–448.
Schwarz, E.R., Speakman, M.T., Patterson, M., Hale, S.S., Isner, J.M., Kedes, L.H.,
Kloner, R.A., 2000. Evaluation of the effects of intramyocardial injection of DNA
expressing vascular endothelial growth factor (VEGF) in a myocardial infarction
model in the rat—angiogenesis and angioma formation. J. Am. Coll. Cardiol. 35
(5), 1323–1330.
Shiojima, I., Sato, K., Izumiya, Y., Schiekofer, S., Ito, M., Liao, R., Colucci, W.S., Walsh, K.,
2005. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes
to the transition to heart failure. J. Clin. Investig. 115 (8), 2108–2118.
Smeets, P.J.H., Teunissen, B.E.J., Willemsen, P.H.M., van Nieuwenhoven, F.A., Brouns, A.E.,
Janssen, B.J.A., Cleutjens, Jack P.M., Staels, B., van der Vusse, G.J., van Bilsen, M., 2008.
Cardiac hypertrophy is enhanced in PPARa/ mice in response to chronic
pressure overload. Cardiovasc. Res. 78, 79–89.
Strauss, B.E., Bajgelman, M.C., Costanzi-Strauss, E., 2005. A novel gene transfer
strategy that combines promoter and transgene activities for improved tumor
cell inhibition. Cancer Gene Ther. 12 (12), 935–946.
Strauss, B.E., Costanzi-Strauss, E., 2004. pCLPG: a p53-driven retroviral system.
Virology 321 (2), 165–172.
Su, H., Joho, S., Huang, Y., Barcena, A., Arakawa-Hoyt, J., Grossman, W., Kan, Y.W.,
2004. Adeno-associated viral vector delivers cardiac-speciﬁc and hypoxia-
inducible VEGF expression in ischemic mouse hearts. Proc. Natl. Acad. Sci.
USA 101 (46), 16280–16285.
Tirziu, D., Simons, M., 2005. Angiogenesis in the human heart: gene and cell
therapy. Angiogenesis 8 (3), 241–251.
Tsukamoto, O., Minamino, T., Okada, K., Shintani, Y., Takashima, S., Kato, H., Liao, Y.,
Okazaki, H., Asai, M., Hirata, A., Fujita, M., Asano, Y., Yamazaki, S., Asanuma, H.,
Hori, M., Kitakaze, M., 2006. Depression of proteasome activities during the
progression of cardiac dysfunction in pressure-overloaded heart of mice.
Biochem. Biophys. Res. Commun. 340 (4), 1125–1133.
Vera Janavel, G., Crottogini, A., Cabeza Meckert, P., Cuniberti, L., Mele, A., Papou-
chado, M., Fernandez, N., Bercovich, A., Criscuolo, M., Melo, C., Laguens, R.,
2006. Plasmid-mediated VEGF gene transfer induces cardiomyogenesis and
reduces myocardial infarct size in sheep. Gene Ther. 13 (15), 1133–1142.
M.C. Bajgelman et al. / Virology 476 (2015) 106–114114
